Mostrando 10 resultados de: 17
Filtros aplicados
Publisher
OMICS A Journal of Integrative Biology(5)
Drug Metabolism and Drug Interactions(3)
Bioanalysis(1)
Biomedical Reports(1)
Current Pharmaceutical Biotechnology(1)
Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopusA rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity
ArticleAbstract: Background: The analytical method here reported for the CEIBA cocktail approach has been developed aPalabras claves:Autores:Adrián LLerena, de Andrés F., Sosa-Macías M.G.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCan the CEIBA cocktail designed for human cytochrome P450 enzymes be used in the rat for drug interaction studies?
ArticleAbstract: Purpose - The CEIBA cocktail consisting of caffeine (CAF), omeprazole (OZ), dextromethorphan (DM) anPalabras claves:Autores:Adrián LLerena, Alves G., de Andrés F., Falcao A.C., Magalhães P.Fuentes:scopusFrequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin
ArticleAbstract: The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed suPalabras claves:Cytochrome P450 2C9, DIABÉTES, Glibenclamide, Glycated hemoglobin A1c, MetforminAutores:Adrián LLerena, Castillo-Nájera F., Cuautle-Rodríguez P., de Andrés F., Molina-Guarneros J.A., Rodríguez-Rivera N.S.Fuentes:scopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusEffects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations
ArticleAbstract: In a one-way cross-over study, we investigated the effect of Khat, a natural amphetamine-like psychoPalabras claves:Autores:Adrián LLerena, Aklillu E., Bedada W., de Andrés F., Engidawork E., Hussein J.Fuentes:scopusMultiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach
ArticleAbstract: Phenotyping of the CYP450 enzyme activities contributes to personalized medicine, but the past phenoPalabras claves:Autores:Adrián LLerena, Bovera M., de Andrés F., Enrique Terán, Humberto Fariñas, Santiago TeránFuentes:googlescopusHigh frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopus